Stockwinners Market Radar for September 05, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Tenon Medical Inc trading halted, news pending

18:47 EDT Caterpillar CEO: We're benefitting from the diversity of our end markets - In an interview on CNBC's Mad Money, Jim Umpleby said some markets have been depressed, but the company still produced great results in Q2. Backup generators for data centers is becoming a very strong business for Caterpillar, he noted. The residential side of the business has proved resilient despite the housing shortage, he added. Umpleby expects the electrification of engines to benefit the mining business over time.

17:43 EDT LGI Homes closed 610 homes in August 2024 - As of August 31, 2024, the company had 132 active selling communities.

17:36 EDT Build-A-Bear announces exclusive multi-year deal with Kansas City Chiefs - Build-A-Bear Workshop announced an exclusive multi-year deal with the back-to-back Super Bowl Champion Kansas City Chiefs. Among other ongoing brand building opportunities, Build-A-Bear will be the presenting partner of both the popular team mascot, "KC Wolf," and the Chiefs digital Fan Cam experience focused on game attendees tagging themselves in a high-resolution, full-stadium picture as well as locating a Build-A-Bear in the stands during each home game for the chance to win a special prize. This collaBEARation between the two Missouri-based organizations also makes Build-A-Bear the "official bear" brand of the storied team.

17:17 EDT Lululemon CEO buys $1.04M in common stock - In a regulatory filing, Lululemon disclosed that its CEO Calvin McDonald bought 4K shares of common stock on September 3rd in a total transaction size of $1.04M. Shares are up about 1% afterhours at $256.

17:12 EDT BAE Systems awarded $121.39M government contract - BAE Systems was awarded a $121.39M modification to a contract for production of M2A4 and M7A4 Bradley vehicles from various inducted legacy source variants. Work locations and funding will be determined with each order, with an estimated completion date of May 31, 2026. Army Contracting Command is the contracting activity.

17:00 EDT Rockwell Automation announces $1B share repurchase program - Rockwell Automation announced its Board of Directors authorized the company to expend up to an additional $1B to repurchase shares of Rockwell Automation common stock. This is in addition to the authorization on May 2, 2022, to repurchase $1B worth of common stock, of which approximately $353M was remaining as of Sept. 5, 2024.

17:00 EDT Avangrid receives FERG approval of Iberdola acquiring rest of company - Avangrid (AGR) announced that it has received Federal Energy Regulatory Commission, FERC, approval of Iberdrola's acquisition of the remaining 18.4% of the issued and outstanding shares of common stock of Avangrid that it does not currently own.

16:46 EDT UiPath jumps 9% to $13.92 after Q2 results, guidance raise

16:40 EDT Tilly's reports Q2 SSS down 7.8% - Total comparable net sales, including both physical stores and e-commerce, decreased by 7.8% relative to the shifted 13-week period ended August 5, 2023.

16:37 EDT Bowlero reports Q4 SSS up 6.9%

16:35 EDT PennantPark expands joint venture, Pantheon to invest additional $75M - PennantPark Investment announced it has agreed to expand its investment in PennantPark Senior Loan Fund, its unconsolidated joint venture with the private credit investment business of Pantheon Ventures or Pantheon. This strategic transaction further strengthens the partnership between PNNT and Pantheon, which was put into place over four years ago, and has generated strong returns to date. PNNT has agreed to invest an additional $52.5 M in capital, and Pantheon has agreed to invest an additional $75.M of capital, thereby resulting in a pro forma JV ownership of 54.8% and 45.2%, respectively. In addition, PSLF is increasing its senior secured credit facility provided by BNP Paribas from $325M to $400M thereby allowing the JV to scale its investment portfolio to over $1.5 B , representing a nearly $500 million increase in the JV's investment capacity. "We are proud of the partnership and the strong returns the JV has generated," stated Art Penn, Chief Executive Officer of PNNT. "The core middle market represents a differentiated investment opportunity for investors in direct lending. The increase in the JV will position PNNT's shareholders to benefit from investments in today's attractive vintage of core middle market senior secured loans."

16:33 EDT Bit Digital reports August BTC production down 11.7% from prior month - Bit Digital announced its unaudited digital asset production, HPC services revenue, and corporate updates for the month of August 2024. The company had 256 servers actively generating revenue from its initial Bit Digital AI contract, as of August 31, 2024. The company earned approximately $4.3M n of unaudited revenue from this contract during the month of August 2024. In August 2024, the company produced 53.4 BTC, an 11.7% decrease compared to the prior month. The company's active hash rate was approximately 2.43 EH/s as of August 31, 2024. Treasury holdings of BTC and ETH were 682.4 and 27,331.0 with a fair market value of approximately $40.2M and $68.7M, respectively, on August 31, 2024. The BTC equivalent of digital asset holdings as of August 31, 2024, was approximately 1,858.3 or approximately $109.6M. The company had cash and cash equivalents of $106.9M and total liquidity of approximately $216.5M, as of August 31, 2024.

16:31 EDT Asur reports August passenger traffic down 2.8% y/y - Asur, an international airport group with operations in Mexico, the U.S. and Colombia, announced that passenger traffic for August 2024 reached a total of 6M passengers, representing a decrease of 2.8% compared to August 2023. Passenger traffic presented year-on-year increases of 16.3% in Colombia and 1.6% in Puerto Rico, while Mexico reported a decrease of 10.7%. Passenger traffic growth in Colombia was driven by increases of 24.8% in international traffic and 14.1% in domestic traffic. Puerto Rico reported 21.6% growth in international traffic and a decrease of 0.7% in domestic traffic. Mexico, in turn, reported declines in domestic and international traffic of 9.1% and 12.6%, respectively.

16:28 EDT Smartsheet reports Q2 ARR up 17% y/y - Reports Q2: Annualized recurring revenue ("ARR") was $1.093 billion, an increase of 17% year over year; Average ARR per domain-based customer was $10,291, an increase of 16% year over year; Dollar-based net retention rate was 113%; Number of all customers with ARR of $100,000 or more grew to 2,056, an increase of 23% year over year; Number of all customers with ARR of $50,000 or more grew to 4,140, an increase of 17% year over year; Number of all customers with ARR of $5,000 or more grew to 20,198, an increase of 6% year over year.

16:22 EDT Costco reports August comparable sales up 5% - Reports August net sales $19.93B, up 7.1%.

16:20 EDT VICI Properties increases quarterly dividend by 4.2% to 43.25c per share - The dividend will be payable on October 3, 2024 to stockholders of record as of the close of business on September 18, 2024.

16:18 EDT TriNet appoints Sidney Majalya as Chief Legal Officer - TriNet has announced the appointment of Sidney Majalya as SVP, Chief Legal Officer and Secretary, effective September 16. Majalya succeeds Samantha Wellington, EVP, Business Affairs, Chief Legal Officer and Secretary who is departing after eight years with the company to pursue another opportunity. Majalya most recently served as TriNet's VP and Deputy General Counsel. Before that, he was EVP, Chief Risk Officer and Deputy General Counsel at Binance.US. Prior to Binance.US, Majalya held senior leadership roles at Intel, Uber Technologies and Oracle. He also previously served as a trial attorney in the Antitrust Division of the U.S. Department of Justice.

16:17 EDT American Water receives IURC approval to acquire Silver Creek Water - Indiana American Water received approval from the Indiana Utility Regulatory Commission for the acquisition of the Silver Creek Water Corporation for $45 million. The closing is expected by mid-November and comes nearly a year after members of the SCWC voted in favor of INAW to become their provider of water service to customers in Clark and Floyd Counties in southern Indiana. Under the agreement, approximately 8,000 water customers will be joining the nearly 1 in 5 Hoosiers currently served by INAW.

16:11 EDT Amcor announces senior executive appointments - Amcor announced senior executive appointments designed to help accelerate organic growth in the business. Fred Stephan, previously President, Amcor Flexibles North America, has been appointed to the newly introduced role of COO. Fred will report to the CEO and will be responsible for enhancing the company's ability to leverage and accelerate profitable growth opportunities across the global flexible packaging businesses, ensuring coordinated execution between business operations and commercial teams. David Clark, previously Amcor Vice President, Sustainability, has been appointed to the new Chief Sustainability Officer role. In this role David will report directly to the CEO and have responsibility for Amcor's sustainability strategies and policies, overseeing their implementation across the company.

16:09 EDT Amneal Pharmaceuticals announces FDA approval of BORUZU - Amneal Pharmaceuticals and Shilpa Medicare Limited announced U.S. Food and Drug Administration approval of BORUZU(TM), a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. BORUZU, a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade(R), a lyophilized powder requiring reconstitution before use. Shilpa developed the molecule and Amneal will manufacture and commercialize the product. BORUZU is expected to launch with a unique J-code in the second quarter of 2025.

16:08 EDT Helen of Troy announces new $500M buyback - Helen of Troy announced that its Board of Directors has authorized the repurchase of $500 million of its outstanding common shares in keeping with its stated intention to opportunistically return to shareholders capital not otherwise deployed for core business growth or strategic acquisitions. The authorization was approved as part of the Board's regular process of reviewing the Company's capital allocation and existing authorization. It is effective August 20, 2024, for a period of three years and replaces Helen of Troy's existing repurchase authorization, of which approximately $245.3 million remained at the time the new authorization was approved.

16:05 EDT Vor Bio announces new data, plans to approach FDA on trial design by year-end - Vor Bio announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg . The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. "We are encouraged by this data and the potential benefit that trem-cel in combination with Mylotarg may offer to patients in a disease that has extremely poor outcomes even after transplant," said Dr. Eyal Attar, Vor Bio's Chief Medical Officer. "With this data, we plan to explore a registrational trial while we continue to pursue other synergistic opportunities for Vor Bio's platform such as VCAR33ALLO and VADC45." The data released today included 18 patients treated with trem-cel of which ten had received Mylotarg as of the data cut-off date of July 19. "All the hope I had in the safety of this approach has been supported by the data from this trial thus far," said Guenther Koehne, MD, PhD, an investigator on the VBP101 study and Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida. "I look forward to treating my next patients at high risk of relapse on this trial as their outcomes are otherwise limited with standard transplants." Vor Bio plans to approach the U.S. Food & Drug Administration to discuss a pivotal trial design for trem-cel + Mylotarg by around year end.

16:00 EDT Performant Financial announces multi-year RAC award from New York State - Performant Financial announced that it has been selected for tentative award of the New York State Medicaid Recovery Audit Contractor, or RAC, with the NYS Office of the Medicaid Inspector General. "This award, following a rigorous competitive bidding process, spans up to five years and includes an initial three-year term with the possibility of two additional one-year extensions. Upon the successful execution of a contract, Performant will utilize its advanced technology and claims review services to perform post-payment assessments on select claims, aiming to identify and rectify any improper payments," the company stated. "We are honored to bring nearly two decades of payment integrity experience to the New York State Medicaid Program. This award not only highlights our success in capturing business from long-standing industry incumbents, but it also represents our inaugural opportunity to serve this significant state Medicaid market, a nationwide market that we believe generates between $300 to $500 million in annual revenue. Performant was chosen for its exceptional value, and we are excited to apply our proven capabilities to complement OMIG's robust program integrity efforts," said Simeon Kohl, Chief Executive Officer.

15:18 EDT Steel Dynamics files trade petitions on corrosion resistant flat rolled steel - Steel Dynamics announced that it petitioned the Department of Commerce and the U.S. International Trade Commission to apply antidumping duties against imports of corrosion resistant flat rolled steel, or CORE, from Australia, Brazil, Canada, Mexico, the Netherlands, South Africa, Taiwan, Turkey, UAE, and Vietnam, and countervailing duties against imports of CORE from Brazil, Canada, Mexico, and Vietnam. The company was joined by four other organizations in at least one or more of these cases, Steel Dynamics stated. "Between the first half of 2023 and the first half of 2024, imports of CORE from the ten subject countries surged from less than 1.25 million tons to almost two million tons, a significant 57 percent increase. The surge of unfairly traded imports of CORE has had a significant negative impact on the domestic steel industry's volume, prices, and profits, necessitating these cases," said Barry Schneider, President and Chief Operating Officer. "Under the unfair trade statutes, the DOC must determine whether to initiate the requested investigations within 20 days, and the ITC must make a preliminary determination of injury within 45 days. Subject to initiation, the company expects preliminary determinations on subsidies later this year and on dumping early next year, though these determinations are subject to extension. Final rulings by both agencies should be completed by October 2025," the company noted.

13:42 EDT Ayr Wellness secures conditional approval to establish vertical operations in VA - AYR Wellness was awarded conditional approval to serve as a pharmaceutical processor by the Virginia Cannabis Control Authority for Virginia's Health Service Area 1. HSA 1 encompasses various cities and counties in Virginia, including Charlottesville, Fredericksburg, Spotsylvania, and Stafford. Upon receipt of the pharmaceutical processing permit, the Company will be permitted to cultivate and process cannabis, manufacture cannabis products, and perform sales to qualified medical cannabis patients in Virginia. The Company must meet any conditional commitments within one year to obtain a full pharmaceutical processor permit.

13:18 EDT Smartsheet up 7% following Reuters report on private equity buyout talks

13:12 EDT Smartsheet trading halted, volatility trading pause

12:01 EDT Vestis Corp trading halted, volatility trading pause

12:00 EDT Yext rises 9.3% - Yext is up 9.3%, or 46c to $5.38.

12:00 EDT Movado falls -11.9% - Movado is down -11.9%, or -$2.68 to $19.90.

12:00 EDT C3.ai falls -12.5% - C3.ai is down -12.5%, or -$2.87 to $20.14.

11:38 EDT First Majestic Silver trading resumes

11:23 EDT Allegiant announces resignation of Chief Marketing Officer Scott DeAngelo - Allegiant announced that Scott DeAngelo, executive vice president and Chief Marketing Officer, has resigned. His last day with the company will be Sept. 30. "To ensure continuity and progress, Drew Wells will assume the position of Chief Commercial Officer, taking over DeAngelo's responsibilities in addition to the revenue and network planning departments," the company stated.

10:43 EDT Big Tree Cloud Holdings Ltd trading resumes

10:34 EDT Hoth announces expansion of clinical sites for HT-001 Phase 2a trial - Hoth Therapeutics received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.

10:26 EDT U.K.'s CMA launches investigation into Ticketmaster over Oasis concert sales - The U.K.'s Competition and Markets Authority announced that it has launched an investigation into Ticketmaster regarding the sale of Oasis tickets for the band's upcoming reunion tour, including how so-called "dynamic pricing" may have been used. The CMA is scrutinizing whether the sale of Oasis tickets by Ticketmaster may have breached consumer protection law. The CMA is at the initial stage of its investigation and will now be engaging with Ticketmaster and gathering evidence from various other sources, which may include the band's management and event organizers. It should not be assumed that Ticketmaster has broken consumer protection law. The CMA will also consider whether it is appropriate to investigate the conduct of anyone else in relation to the matter. The CMA is separately considering broader competition and consumer issues raised by so-called "dynamic pricing." The letter notes that the government may include measures relating to "dynamic pricing" in its ticketing consultation, and the CMA will assist the government should it seek to develop policy in this area. Reference Link

10:16 EDT Lockheed Martin to deliver two C-130J-30 airlifters to Egyptian Air Force - The Egyptian Armed Forces announced at the Egypt International Air Show that Lockheed Martin will deliver two C-130J-30 Super Hercules tactical airlifters to the Egyptian Air Force through a Foreign Military Sale with the U.S. Air Force. Egypt is the 23rd nation to join the worldwide Super Hercules operating community, Lockheed said.

10:00 EDT WPP rises 6.0% - WPP is up 6.0%, or $2.80 to $49.28.

10:00 EDT Yext rises 15.0% - Yext is up 15.0%, or 74c to $5.66.

10:00 EDT Movado falls -12.4% - Movado is down -12.4%, or -$2.80 to $19.78.

09:54 EDT Work Medical Technology Group Ltd trading resumes

09:48 EDT Toro Company falls -12.7% - Toro Company is down -12.7%, or -$11.53 to $79.47.

09:48 EDT C3.ai falls -15.9% - C3.ai is down -15.9%, or -$3.67 to $19.34.

09:47 EDT a.k.a. Brands rises 5.9% - a.k.a. Brands is up 5.9%, or $1.33 to $23.77.

09:35 EDT Zimmer Biomet sees ERP implementation impacting FY24 sales by about 1% - Says addressing "inconsistent" U.S. performance. Believes company can deliver mid-single digit revenue with EPS growing faster than revenue. Notes that the company moved from legacy ERP platform in July to SAP, says "things worked well at first," identified it didn't work as expected, which will create some challenges in revenue in 2H24. Zimmer Biomet says situation is well managed, and it understands the root cause, but that it will impact 2H24 revenue. Says impact could be about 1% to FY24 sales. Comments taken from the Wells Fargo Healthcare Conference. Shares of Zimmer Biomet are down 7.5% in early trading to $105.87.

09:30 EDT Sino-Global Shipping America trading halted, volatility trading pause

09:23 EDT M2i Global, Regenerate partner to transform battery technology - M2i Global and Regenerate Technology Global are pleased to announce a partnership aimed at transforming battery technology and the recycling of battery metals. The two companies will partner to construct a battery recycling facility on Hawthorne Military Facility in Nevada. The joint venture continues M2i's dedication to supporting the US government and military to process and store critical minerals that are essential to reliable and sustainable energy sources, and provide technologies for energy innovation. In that vein, Regenerate's patented and proprietary processes provide several benefits which solve environmental mandates while creating valuable, high-demand products. The technology, developed in partnership with Cambridge University Material Science Labs, substantially reduces energy consumption by 80% plus, minimizes greenhouse gas emissions by 90%, and virtually eliminates toxic sludge associated with conventional recycling processes. While doing so, the Regenerate "upcycling" process increases the density of lead-acid batteries by 40%. In an era where renewable energy is more critical than ever, M2i and Regenerate are committed to ensuring that the materials vital to this transformation are sourced and recycled ethically and sustainably. This partnership is a significant step towards achieving a greener and more prosperous future.

09:21 EDT 1933 Industries director Rick Skeith resigns - 1933 Industries announces that Mr. Rick Skeith has tendered his resignation from the Board of Directors effective immediately.

09:18 EDT Cyclo Therapeutics presents data from study, substudy of Trappsol Cyclo - Cyclo Therapeutics announced the presentation of preliminary data from its ongoing pivotal Phase 3 study and substudy evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1. The data were presented in two poster presentations at the SSIEM Annual Symposium 2024 being held September 3-6 in Porto, Portugal. The TransportNPC study is the most comprehensive controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes of an investigational therapy for NPC1. The study completed enrollment in May. Additionally, the company completed enrollment with 10 patients in a substudy per the adopted Paediatric Investigational Plan, or PIP, treating newborn to three years of age. The substudy is evaluating Trappsol Cyclo in the youngest age groups, focusing on its ability to target the visceral aspects of the disease. Administering treatment early in the disease course may lead to the most optimal results and could potentially have a preventative effect on overall symptom development. The company's ongoing Phase 3 study will evaluate change in 5D-NPC-CSS between Trappsol Cyclo and placebo as primary endpoint for the EU. A total of 104 patients have been enrolled into the study and substudy, the majority of patients enrolled fall within the ASIS score limits targeted with the average ASIS at recruitment was 1.04; average age at inclusion was 20.2 years. Average participation time in the blinded phase of the study is 44 weeks as of June 30, 2024. As of June 30, six patients terminated study participation before week 96; following protocol, six patients switched to open-label Trappsol Cyclo before week 96 due to disease worsening. A total of 625 adverse events were reported, 80% were Grade 1 in severity most related to underlying NPC disease; Grade 2 were 16.7%, and Grade 3 were 5.3%. Serious adverse events reported, possibly related or related to treatment. One patient death unrelated to study-drug. No patients have withdrawn due to safety concerns. Safety profile found consistent with that of completed studies. Topline data from the 48-week interim analysis is anticipated for H1 2025. Should the 48-week interim data meet statistical significance, the company, in alignment with the FDA and EMA, intends to submit marketing applications for approval based on the 48-week interim data. The goal of the substudy is to evaluate the safety of biweekly IV Trappsol Cyclo for 192 weeks in very young patients, in order to obtain descriptive data regarding safety, global severity, and improvement in response to HPssCD from investigators and patients/caregivers. Ten patients were recruited, of which two terminated the study after 48 weeks. AE profile is in line with prior findings from compassionate use, from earlier studies, and from a double-blind Phase 3 study running in parallel. Overall, AEs are limited, majority are mild or moderate and 1 AE severe; most considered unrelated to study drug. No SAEs were considered as related to or possibly related to study drug. At baseline patients had a mixture of very mild to severe disease based on CGI. Progress in patients with neurological symptoms from the early pediatric age is understood to be more rapid than in patients with late pediatric, juvenile, or even adult neurological onset of NPC. Disease progression is carefully monitored throughout duration of the study. The substudy has completed enrollment and the treatment has been well tolerated with a safety profile consistent with prior studies, including the larger TransportNPC study. In addition to the clinical endpoints, this study will provide additional critical information to address the concept of early intervention and prevention of disease progression. By the first half of 2025, all currently enrolled patients will have completed at least 48 weeks of treatment; Three patients will likely have completed 96 weeks of treatment. This will be the first data in NPC1 on treatment in this age group over a period of 48 weeks.

09:17 EDT Mullen's Bollinger Motors enters partnership with Texas Consulting & Development - Mullen Automotive's Bollinger Motors has reached an agreement to partner with Texas Consulting & Development to supply Bollinger B4 Class 4 trucks as part of TCD's new, bundled service offering to ports and other related industries. The agreement strengthens TCD's vehicle portfolio and enhances the company's Vehicle-to-Grid and Vehicle-to-Building technology offerings. In addition, TCD will leverage the Bollinger B4 electric truck to stimulate sales across the commercial & industrial, telecom and utility sectors. This strategic move is expected to enhance market penetration and provide comprehensive solutions to a broader range of industries for Bollinger Motors.

09:13 EDT Progress Software announces early-access release of MarkLogic Server 12 - Progress announced the early-access release of Progress MarkLogic Server 12. With this release, Progress expands on the proven search capabilities within MarkLogic Server by delivering native vector support and new relevance-based algorithms to provide advanced capabilities for customers to harness the power of AI in the enterprise. Customers can now more easily integrate generative AI in their enterprise applications with a flexible Retrieval Augmented Generation, RAG, pattern and securely ground LLM models in their private data to enable fact-based query responses generated from AI models.

09:12 EDT Nexalin Technology participates in Congressional roundtable - Nexalin Technology announced its participation in a high-profile Congressional roundtable in North Carolina, focused on emerging virtual therapeutic options for opioid treatment. The event was hosted by the Breaking Barriers for Substance Use Recovery initiative and featured key stakeholders from across the healthcare and policy spectrum. The roundtable, held with Dr. Greg Murphy, U.S. Congressman representing North Carolina's 3rd District, centered on the deployment of virtual-based opioid therapy models across the country. Dr. Murphy, Congress' only actively practicing physician, serves on the Health Subcommittee of the Veterans Affairs Committee and is a strong advocate for innovative healthcare solutions, particularly those aimed at addressing the opioid crisis. The invitation-only roundtable brought together thought leaders and innovators to discuss the potential of virtual therapies to overcome the stigma and geographic barriers often associated with traditional in-clinic treatment options. Nexalin's approach to virtual therapeutic solutions, which is expected to play a significant role upon FDA clearance, was highlighted as a promising tool in the fight against opioid addiction. During the discussions, emphasis was placed on establishing stronger practices within the Department of Veterans Affairs and the Substance Abuse and Mental Health Services Administration to encourage the adoption of virtual-based therapies. These therapies, including Nexalin's neurostimulation technology, aim to provide effective treatment options that can be accessed remotely, expanding the reach and impact of mental health care.

09:10 EDT Kartoon Studios to launch Roblox-based competition series for kids - Kartoon Studios announced it will launch a Roblox-based competition series for kids, which will premiere this Fall on the company's rapidly growing streaming service Kartoon Channel. Tapping into the game's massive audience played by over 30 million every day, the third season of Kidaverse Roblox Rumble will have a global premiere in over 60 territories, including North America, Asia, Europe, and The Middle East.

09:09 EDT Shell commences exchange offers of up to twelve series of USD notes - Shell announced the commencement of offers to exchange any and all validly tendered and accepted notes up to a maximum aggregate principal amount of $10 billion of twelve series of notes issued by Shell International Finance B.V. for a combination of cash and a corresponding series of new notes to be issued by Shell Finance US and fully and unconditionally guaranteed by Shell, as described in the table below. Each series of New Notes will have the same interest rate, maturity date, optional redemption date and interest payment dates as the corresponding series of Old Notes for which they are being offered in exchange and other terms that are substantially identical to the Old Notes, except for the issuing entity and other minor exceptions as described in the Prospectus. A Registration Statement on Form F-4 including a preliminary prospectus, which is subject to change, relating to the issuance of the New Notes was filed with the Securities and Exchange Commission today but has not yet been declared effective. The New Notes may not be sold or exchanged for Old Notes, nor may offers to buy be accepted, prior to the time the Registration Statement is declared effective by the SEC. Shell is conducting the Exchange Offers to migrate the existing Old Notes from Shell International Finance B.V. to Shell Finance US Inc. in order to optimize the Shell Group's capital structure and align indebtedness with its U.S. business.

09:08 EDT Curiosity to launch Curiosity University on Prime Video - Curiosity (CURI) has announced that Curiosity University is launching on Prime Video (AMZN) in the U.S. as an add-on subscription for $8.95 per month.

09:07 EDT Cohu announces order for new Diamondx instrument and mixed signal platform - Cohu announced a leading multinational Automotive, Industrial, and Computing customer has selected the Diamondx platform for testing power management devices. This customer ordered an integrated test cell solution including Cohu's Diamondx tester configured with the new VI100 instrument along with major mixed signal platform enhancements paired with Cohu's NY32 handler and cCompact interface. The new VI100 product is a four-quadrant voltage and current instrument that combines high-accuracy DC source and measure, including arbitrary waveform source and capture. Designed to address the increasing complexity and integration of analog and power management ICs, the VI100 is configured with a newly enhanced set of mixed signal instruments, multi-core test computer architectures and databus. The Diamondx now offers up to 80% reduced test time compared to legacy systems at less than half the cost-of-test for competitive-liquid cooled systems. "We are excited to see traction with our Diamondx tester strategy, including the new VI100 instrument, in the mixed signal market and in particular with selection by a top 5 automotive semiconductor manufacturer," commented Luis Muller, Cohu President and CEO. "The Diamondx now offers a scalable platform for testing next generation mixed signal semiconductors used in automotive, industrial, and computing applications, an estimated $860M addressable market."

09:06 EDT Optinose announces peer-review publication on EDS-FLU efficacy - Optinose announced the peer-review publication of a paper titled, "EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials"1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society. In these trials, XHANCE improved symptoms, sinus opacification, and quality of life in both groups of CRS patients either with or without prior sinus surgery, indicating that previous surgery is not required for patients with CRS to experience the benefits of treatment with XHANCE and that XHANCE can be helpful for patients even after surgery.

09:06 EDT Riot Platforms reports August 2024 Bitcoin production down 3% vs. last year - Riot Platforms announced unaudited production and operations updates for August 2024. Riot produced 322 bitcoins produced, down 13% vs. July 2024 and down 3% vs. August 2023. Average Bitcoins produced per day were 10.4 in August, down 13% vs. 11.9 in July 2024 and down 3% vs. August 2023. Riot continued development of the third 100 MW building in the Corsicana Facility, Building B1, and began deploying miners within the building. Building B1 will be fully operational in the month of September. Development has continued on the final 100 MW building in Phase 1, Building B2, and miner deployment will begin during the month of September.

09:05 EDT Shuttle Pharmaceuticals announces issuance of U.S. patent HDAC inhibitors - Shuttle Pharmaceuticals announced the issuance of U.S. Patent No. 12,077,515, titled "Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease." This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma's intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase, HDAC, enzymes. The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways. These inhibitors are being developed as potential treatments for a range of human diseases, including cancer.

09:04 EDT Tigo Energy files patent infringement lawsuit against Zhejiang Benyi New Energy - Tigo Energy announced that the company's Chinese affiliate, Tigo Energy Equipment Trading, has filed a patent infringement lawsuit against Zhejiang Benyi New Energy. The complaint was filed in the Shanghai Intellectual Property Court on August 21. The complaint alleges that certain Zhejiang Benyi New Energ rapid shutdown devices infringe on Tigo IP, specifically China Patent No. 200880114564.0, which relates to rapid shutdown technology. Rapid shutdown is a safety function for photovoltaic systems on buildings, designed to reduce the risk of electrical shock to emergency responders, and is mandated by building codes and regulatory bodies in a rapidly growing number of countries around the world.

08:55 EDT Conduent selected by American Samoa DHSS to modernize ASNAP system - Conduent Incorporated has been selected by the American Samoa Department of Human and Social Services DHSS to modernize and convert the U.S. territory's legacy American Samoa Nutrition Assistance Program ASNAP system. As of 2024, nearly 5,000 needy, elderly, blind or disabled individuals in American Samoa receive ASNAP benefits from the government. These benefits provide essential food assistance to supplement their nutritional needs. Supported by Conduent, ASNAP recipients will be able to receive their benefits through safer and more secure Electronic Benefits Transfer EBT cards. Rather than waiting for paper vouchers to use their benefits, ASNAP recipients will now be able to buy groceries and other items with electronic EBT cards. The conversion to cards will eliminate the risk of losing funds if paper vouchers are lost. Recipients will be able to track and manage their benefits through an online portal, and a new mobile application will allow users to access their benefits information and customer service support directly from their smartphones. The department will also be able to utilize the portal to access information about recipient management and card issuance and comply with federal reporting requirements.

08:48 EDT LQR House enters marketing partnership with Higher Celebrations - LQR House announces its marketing collaboration with Higher Celebrations. The partnership contract was signed in July 2024, and the product is now officially available. Through this partnership, LQR House's influencer network will create engaging, viral content centered around The HotShot. According to the owners of the brand, The HotShot is a revolutionary shot glass that redefines celebrations. It features a candle atop the glass, igniting the atmosphere as guests gather around.

08:45 EDT Jaguar Health celebrates National Service Dog Month - Jaguar Health is proud to be celebrating National Service Dog Month "September is National Service Dog Month. Service dogs are incredible working animals who enable people to live more independently and enjoy a better quality of life. In some cases, service dogs can be the difference between life and death," said Lisa Conte, Jaguar's founder, president, and CEO. "These qualities align with Jaguar's mission of providing supportive care to people and dogs suffering from complex disease states like cancer." Canalevia-CA1, Jaguar's U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is available on Chewy and from veterinarians across the U.S. By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree.

08:44 EDT BK Technologies says BKR 9000 multiband radio receives NIFC approval - BK Technologies announced that the BKR 9000 multiband radio has been approved by the National Interagency Fire Center National Interagency Incident Communications Division as a fire approved radio for use by all federal employees and personnel under contract with the United States federal government. Designation by the NIFC as a fire approved radio qualifies the BKR 9000 for purchase by the Department of the Interior for use in federal wildland fire operations, as well as for use by cooperator aviation radios and forest health protection. As a multiband radio, the BKR 9000 provides agencies with the capability to operate on all four Land Mobile Radio frequency bands, on conventional or P25 trunked radio systems in urban centers such as New York City, in rural communities, and on wildland fire incidents. The BKR 9000 also provides superior interoperability across federal, state, and local agencies, and private contractors working with the NIFC. The BKR 9000 joins the BKR 5000 single band radio which received NIFC approval in March of 2021.

08:43 EDT Gaucho Group's Algodon Fine Wines partners with Barrel & Wines - Gaucho Group Holdings announced the addition of Florida-based distributor, Barrel & Wines, to the wine retailer network of Algodon Fine Wine. This strategic partnership with Barrel & Wines is a pivotal step in Gaucho Holdings' plan to broaden its market reach and increase brand awareness of Algodon Fine Wines across the United States. By leveraging Barrel & Wines' distribution network and established relationships within the Florida market, Gaucho Holdings aims to not only enhance product visibility in retail and restaurant sectors but also to attract new customer segments. The Company is focused on expanding its presence in other key markets through similar partnerships, innovative marketing campaigns, and exclusive wine-tasting events that showcase the unique qualities and heritage of Algodon Fine Wines.

08:41 EDT Femasys to exhibit at CFAS Annual Meeting - Femasys announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26. Kathy-Lee Sepsick, Femasys Founder and CEO commented, "This is an important opportunity to connect with practitioners whose patients and clients would benefit from our suite of products. The conference comes at a particularly opportune moment as we recently announced the Canadian approval of FemVue MINI, our eco-friendly version of our solution for fallopian tube assessment. We continue to advance solutions to improve women's reproductive health worldwide and look forward to demonstrating our portfolio of infertility products, including FemVue MINI and FemaSeed, our next generation artificial insemination product to potential customers."

08:40 EDT Horizon Aircraft commissions survey on small, micro-cap fund managers - New Horizon Aircraft has commissioned a study that indicates a strong return by investors to small and micro-cap companies with unique and sustainable technologies may be imminent. The global study with small and micro-cap fund managers in the US, Canada, Europe, the Middle East and Asia with collectively $82.4 billion assets under management, found that 76% of respondents anticipate the level of exposure to small and micro-caps from institutional investors to increase over the next six to 12 months. One in three fund managers believe allocations could increase by 25% or more. Brandon Robinson, CEO of Horizon Aircraft, commented, "Investors are once again being drawn to smaller public companies that offer much more upside potential. In our case, offering cutting edge aerospace technology that enables a new way to move people and goods around our crowded planet is a perfect example of how smaller companies are helping to build a better, more sustainable future."

08:40 EDT PodcastOne renews exclusive sales agreement with Welch, Sullivan - PodcastOne (PODC), a subsidiary of LiveOne ( LVO), announced that it has renewed its exclusive sales and distribution agreement for the chart topping pop culture podcast I've Had It hosted by Jennifer Welch and Angie "Pumps" Sullivan. "We are proud of our continued relationship with Jennifer and Pumps. These two ladies have created shows that resonate with audiences and advertisers in an increasingly competitive podcast landscape and have shown the masses how to laugh at just how outrageous life has become. It's never not a good idea to tune in and listen to what they've had it with," said Kit Gray, President of PodcastOne.

08:38 EDT Rezolve AI enters partnership with SPH AG - Rezolve AI announces a partnership with SPH AG. This alliance is poised to redefine the future of these industries through the deployment of Rezolve's proprietary AI technologies, including BRAiN Commerce, BRAiN Checkout, and BRAiN Assistant. "We are thrilled to collaborate with SPH AG to bring our cutting-edge AI solutions to the fashion, sports, lifestyle, and retail industries," said Daniel M. Wagner, CEO and Chairman of Rezolve AI. "Our partnership will enable companies to transform their operations and drive exponential growth in the digital age."

08:36 EDT Carmell Therapeutics launches skincare partnership with Ladies Playbook - Carmell announced a strategic partnership with Ladies Playbook, an exclusive community dedicated to providing support, information, and the connections for an NFL family to thrive wherever their football career takes them. This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome, through the expansion of its direct-to-consumer and e-commerce customer channels as well as driving toward influential franchise initiatives like Ladies Playbook.

08:36 EDT Better Choice Company provides shareholder update on balance sheet - Better Choice Company provides shareholders with an update on its pro-forma and as-adjusted balance sheet. Michael Young, Better Choice Chairman of the Board, commented, "We are pleased to provide our shareholders with an update on our balance sheet, before the anticipated closing of our acquisition of SRx Health. Net of debt, Better Choice cash and other current assets as of June 30, 2024 was $3.94 per share. After the closing of our SRx acquisition, we believe there to be additional value to our shareholders." As of June 30, 2024, on a pro-forma and as-adjusted basis, Better Choice had an adjusted net tangible book value of $10.9 million, or $4.07 per share. Additionally, pro-forma and as-adjusted net current asset value was $10.6 million, or $3.94 per share2. The pro-forma and as-adjusted values give effect to: the consummation of the Company's registered public offering of its common stock and prefunded warrants as described in the Company's prospectus filed with the SEC on July 31, 2024; and payment of $4.7 million of trade accounts payable at an approximate 56% discount pursuant to the previously announced settlement agreement entered into on June 20, 2024 with Alphia, Inc. As previously announced, Better Choice has entered into a definitive agreement to acquire SRx Health Solutions. The transaction has been approved by the Board of Directors of both companies. The closing of the transaction is subject to customary closing conditions, including the receipt of required stockholder approvals from SRx Health and Better Choice. The transaction is expected to close in the fourth quarter of 2024.

08:34 EDT Intelligent Bio announces progress to plan required for FDA 510k submission - Intelligent Bio Solutions announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission. Harry Simeonidis, President and CEO at INBS, commented, "Our team and CRO partner are working together effectively to remain on track with our plan to complete the in-clinic portion of the method comparison study by the end of September. This progress aligns with our overarching goal of preparing a 510(k) submission for the FDA in the fourth calendar quarter of 2024."

08:33 EDT Indaptus Therapeutics to initiate dosing of patients at higher Decoy20 dose - Indaptus Therapeutics provides an update regarding key clinical advancements.The independent Safety Review Committee overseeing the Company's Phase 1 clinical trial convened in August to review the safety data at the higher Decoy20 dose with single dose administration and the safety data at the lower Decoy20 dose with weekly administration. The encouraging data has led to the decision to: Continue dosing additional patients at the lower Decoy20 dose on a weekly schedule; Initiate dosing patients at the higher Decoy20 dose on a weekly schedule

08:32 EDT Core Scientific reports August self-mining bitcoin earned 358 vs. 411 in July - Core Scientific, released unaudited production and operations updates for August 2024."Our team has been very busy preparing some of our sites for modification to support our HPC hosting contracts and optimizing operations at our bitcoin mining sites," said Adam Sullivan, Core Scientific's Chief Executive Officer. "We have removed bitcoin mining infrastructure from two of our existing facilities in preparation for selective interior demolition and have redeployed the miners removed from those facilities to our bitcoin mining sites. The sequential decline in self-mined bitcoins earned resulted from a combination of miners migrating to their new data centers and continued growth in global network hash rate and difficulty." "A great deal of work lies ahead as we focus on delivering 382 contracted megawatts of infrastructure for HPC through 2026 and aim to secure additional sites for new clients this year. Our team is engaged, aligned and excited about Core Scientific's future. Reports Self-Mining Bitcoin Earned 358 in August vs. 411 in July.

08:32 EDT Enerpac Tool completes acquisition of DTA - Enerpac Tool Group announced that it completed the acquisition of Madrid, Spain-based DTA The Smart Move, DTA, a global leader in the industrial heavy loads transportation industry, designing and manufacturing mobile robotic solutions. The purchase price is EUR 24 million plus potential for a three-year earn-out tied to the achievement of certain financial objectives. The purchase price will be funded with a combination of cash on hand and borrowings from the Company's credit facility.

08:27 EDT Rail Vision granted U.S. patent for AI-powered obstacle detection system - Rail Vision announced the approval of its U.S. patent for a cutting-edge AI-based railway obstacle detection system by the United States Patent and Trademark Office in August. This milestone reflects Rail Vision's unwavering commitment to advancing railway safety through revolutionary technology, poised to reshape the industry. The newly patented system combines advanced electro-optical imaging with artificial intelligence, offering innovative protection against obstacles on and off rail tracks. Through advanced AI algorithms, including deep learning and convolutional neural networks, the system provides real-time analysis of the railway path, detecting potential hazards with unprecedented accuracy. This technology significantly enhances awareness for train drivers and operators alike, aiming to preserve business continuity by dramatically reducing collisions and improving safety for freight and passengers.

08:21 EDT Perpetua Resources' Stibnite Gold Project approved by U.S. Forest Service - Perpetua Resources announced that the U.S. Forest Service - USFS - has completed the Final Environmental Impact Statement and is issuing a Draft Record of Decision authorizing the Stibnite Gold Project. Based on the USFS schedule published in July, the Final Record of Decision is anticipated by the end of 2024. The decision comes after the completion of interagency permitting review, scientific evaluation, and public input. The Project is designed to provide environmental benefits to an abandoned mine site while producing gold and unlocking the only reserve of antimony within the U.S. Perpetua's Stibnite Gold Project is positioned to be one of the highest-grade open pit gold projects in the United States with 4.8M ounces of estimated gold reserves. The Project is expected to produce over 450K ounces of gold annually over the first four years with all-in sustaining costs under $450 per gold ounce based on the 2020 Feasibility Study. As a by-product of gold production, the Project has a reserve of 148 million pounds of antimony. Antimony is essential for national defense, clean energy and technology applications, yet no domestically mined supply currently exists. Beginning on September 15, China, which is responsible for nearly half of all global mined antimony output and dominates global refinement and processing, has announced that it will restrict antimony exports.

08:17 EDT Moderna announces EMA CHMP adopted positive opinion on updated Spikevax - Moderna announced that the European Medicines Agency's, EMA, Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Moderna's updated COVID-19 vaccine for the autumn/winter season 2024-2025.

08:15 EDT Lottery.com completes acquisition of S&MI - Lottery.co announces the successful completion of its acquisition of S&MI, the technology company behind the Sports.com brand and app. The consideration for the acquisition, finalized on September 1, 2024, is all in common stock of Lottery.com valued at $3.00 per share.

08:14 EDT Daxor receives $300K matching fund award from Launch Tennessee - Daxor Corporation announces Launch Tennessee awarded Daxor Corporation a $300K SBIR matching fund to advance its next-generation point-of-care blood volume analyzer, building on Daxor's Phase II award from the Defense Health Agency. "This award is a welcome addition to Daxor's long-standing and robust portfolio of non-dilutive funding, which focuses on leveraging public funding to empower clinicians with advanced tools for optimal fluid management to enhance patient outcomes," said Michael Feldschuh, CEO and President of Daxor. "This award highlights our unwavering commitment to innovation, job creation, and our enduring presence in Oak Ridge. We are proud to be part of the vibrant Tennessee community and grateful for this recognition."

08:13 EDT Spectral AI awarded additional funding from MTEC - Spectral AI announced that it has received a new award of over $850,000 from the Medical Technology Enterprise Consortium, MTEC. This award will support the ongoing development of DeepView SnapShot M, Spectral AI's handheld predictive burn wound healing device targeted for use in battlefield assessment that is based on the Company's AI-driven DeepView System platform.

08:11 EDT Ocean Power completes long term testing of next gen PowerBuoy - Ocean Power Technologies announced it has completed more than four months of offshore testing of its Next Generation PowerBuoy in the Atlantic Ocean off New Jersey. The solar and wind power equipped Next Generation PB was equipped with OPT's proprietary Artificial Intelligence capable Merrows suite of solutions. The system maintained 100% data uptime and the state of charge of the batteries remained over 90% throughout the deployment. During the deployment, several Intelligence, Surveillance, and Reconnaissance demonstrations for potential customers were completed.

08:10 EDT Arcutis Biotherapeutics completes enrollment of Phase 1b study on ARQ-255 - Arcutis Biotherapeutics announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255, a topical suspension of ivarmacitinib, a potent and selective JAK1 inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis' proprietary 4D technology to deliver drug deep into the skin to the base of the hair follicle, the site of the inflammation that underlies alopecia areata. Results from the study are expected to be reported in the first half of 2025.

08:08 EDT Replimune appoints Balachandran to board of directors - Replimune Grou announced that Madhavan Balachandran was elected to Replimune's Board of Directors at the Company's annual meeting of stockholders.

08:08 EDT Allurion Technologies: Allurion Program safe and effective in adolescents - Allurion Technologies announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents... Task Force concluded that the evidence for the use of pharmacotherapy-including GLP-1 drugs-was inadequate in children and adolescents.... This study affirms Allurion's belief that the Allurion Balloon represents a novel, non-invasive, safe, and effective treatment option for adolescents which can allow for earlier intervention in the treatment of obesity. "Bariatric surgery and long-term pharmacotherapy, although effective in adults, raises concerns about invasiveness and potential risks when applied to adolescents," said Dr. Ram Chuttani, Chief Medical Officer of Allurion. "We believe that the results of this study mark a significant milestone in the treatment of adolescent obesity, as the Allurion Balloon offers a non-invasive treatment option without several of the issues related to surgery and medications."

08:07 EDT Enovis to unveil Tarsoplasty Percutaneous Lapidus System at AOFAS Meeting - Enovis will unveil its new Tarsoplasty Percutaneous Lapidus System and offer live demonstrations of Better Step, a patient-focused platform, alongside other advanced product offerings at the American Orthopaedic Foot & Ankle Society annual meeting in Vancouver, British Columbia from September 11-14, 2024. At the meeting, Enovis will unveil the Tarsoplasty Percutaneous Lapidus System, an innovative approach to the Lapidus bunionectomy that features next generation instruments and implants for a more guided, reproducible percutaneous procedure-enabling surgeons to reduce operative time and improve recovery outcomes for patients. In addition to the Tarsoplasty System, Enovis will offer live demonstrations of Better Step, a patient-focused platform designed to enhance the patient experience throughout the bunion surgery journey. The app encourages physicians to deliver personalized care through custom videos, educational materials, and recovery protocols tailored to each patient's needs.

08:06 EDT Hoth Therapeutics announces positive data from skin toxicities with HT-001 - Hoth Therapeutics announced positive data from the treatment of epidermal growth factor receptor inhibitor - EGFRI - associated papulopustular eruptions with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptoms, marking a significant advancement in managing a common and debilitating side effect experienced by cancer patients undergoing EGFRI therapy. In the reported case, the patient, a 59-year-old female undergoing treatment for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days. Over the following three weeks, no new lesions developed, further highlighting the potential of HT-001 as an effective and safe therapy for EGFRI-associated PPEs. A Phase 2a clinical trial is currently underway to further evaluate the efficacy and safety of HT-001 in the management of EGFRI-associated skin toxicities.

08:04 EDT La Rosa Holdings onboards over 400 agents since June - La Rosa Holdings announced that the Company has onboarded over 400 agents since June 1, 2024. This record growth is due in part to the broad appeal of La Rosa's innovative multi-level, revenue-share commission plan, which is disrupting the real estate industry by increasing transparency, as well as enabling agents to earn revenue immediately and without restrictions. The plan combines immediate earning potential, a five-level structure, and the flexibility of a 100% commission model. In addition, La Rosa Holdings is benefiting from the recent practice changes required for members of the National Association of Realtors under the settlement agreement. These changes have propelled interest from agents looking for more lucrative and sustainable income streams.

08:03 EDT Akebia and U.S. Renal Care initiate trial of Vafseo for patients on dialysis - Akebia and U.S. Renal Care, a privately held kidney care provider, plan to begin a collaborative clinical trial of recently approved Vafseo. The first patient in this trial is expected to be enrolled this year. The Vafseo Outcomes In-Center Experience - VOICE - trial intends to enroll approximately 2,200 patients who will be randomized to oral Vafseo 300 mg tablets administered three times per week or standard-of-care erythropoiesis-stimulating agents. The primary endpoint is all-cause mortality and the secondary endpoint is all-cause hospitalization. The trial was powered to demonstrate non-inferiority for all-cause mortality and superiority for a 10% reduction in all-cause hospitalization.

08:03 EDT Semtech expands distribution footprint in Canada with GetWireless - Semtech Corporation announced expansion of its distribution footprint in Canada with GetWireless, a leading value-added distributor of cellular solutions that connect the Internet of Things IoT..."We are excited to announce that GetWireless is now fully authorized to offer Semtech's IoT connectivity, modules, and router solutions in Canada. Semtech, formerly known as Sierra Wireless, has a distinguished track record of delivering rugged, reliable, and secure solutions for mission-critical applications. With over 20 years of successful partnership in the US between Semtech and GetWireless, we are eager to extend this collaboration into the Canadian market. Together, we look forward to driving data-driven transformation with our cutting-edge and secure technology solutions," said Hieu Duong, head of global channel sales at Semtech.

08:02 EDT Voyager Therapeutics enters license for capsid - Voyager Therapeutics (VYGR) announced that Novartis AG (NVS) has agreed to license a novel capsid generated from Voyager's TRACER capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022. In consideration for the current capsid license, Voyager will receive $15M upfront and is eligible to receive up to $305 million in associated potential development, regulatory, and commercial milestone payments, as well as tiered mid- to high-single digit royalties on a potential product incorporating the licensed capsid for this target.

08:00 EDT First Majestic Silver trading halted, news pending

07:51 EDT ParaZero signs over $200,000 agreement with BladeRanger - ParaZero Technologies has signed an agreement with BladeRanger. The multi-phase agreement is valued at approximately $230,000. As part of the agreement, ParaZero will support regulatory processes with the Israeli Civil Aviation Authority to develop and certify a safe drone operating system for BladeRanger's urban drones. This involves researching regulatory requirements, proposing potential solutions and designing a safety system, hardware and software, that is optimized for BladeRanger's platform, tailored to this market segment and compliant with the Israeli standards and regulations set by the CAA. ParaZero will also provide technical support and coordinate testing to ensure compliance and successful implementation.

07:38 EDT Aehr Test Systems secures first multisystem orders for Sonoma system - Aehr Test Systems announced it has received its first multisystem customer orders for its Sonoma ultra-high-power system for volume production test and burn-in of artificial intelligence processors. This customer is a large-scale data center hyperscaler delivering computing power and storage capacity to millions of individuals and organizations worldwide. These initial orders are for six Sonoma systems, configured for production testing of ultra-high-power AI devices and include turnkey application-specific burn-in modules with active liquid-based conductive temperature control per device. These systems will ship from Aehr's high-volume production facility in Fremont, California over the next six months.

07:37 EDT Ecarx powers launch of Lynk & Co. Z10 flagship luxury sedan - ECARX Holdings (ECX) and AMD (AMD) congratulated Lynk & Co. on the first deliveries of the Lynk & Co. Z10 flagship luxury sedan, which integrates ECARX's Makalu computing platform powered by AMD Ryzen Embedded V2000 processors. The Lynk & Co Z10 officially debuted in Sweden in June 2024, where it showcased the strength of the Makalu computing platform and AMD Ryzen Embedded processors, setting new benchmarks for automotive digital cockpit innovation. The Makalu computing platform is the first to use AMD Ryzen Embedded V2000 processors with integrated AMD Radeon_Graphics, allowing for unparalleled 3D graphics, security, and entertainment features. This platform is unique in the industry, offering state-of-the-art processing capabilities which help ensure robust support for future software enhancements.

07:35 EDT Prairie Operating Co. spuds first well at Shelduck South - Prairie Operating announced the spud of Shelduck South 8E5NCM with Precision E-Drilling Rig 461 in Weld County, Colorado. The Shelduck South development will encompass eight two-mile lateral wells alternating between the Niobrara B and C Chalks. Drilling of all eight wells is expected to be completed by late October. Hydraulic fracturing is anticipated to commence in early November with production beginning by late December. Consistent with the Company's commitment to minimizing environmental impacts, Prairie will utilize Precision's E-rig 461, powered by natural gas generators with battery backup, and expects to fully electrify the Shelduck South production facilities by line power.

07:34 EDT Adverum Biotechnologies reports inducement grants under Nasdaq listing rule - Adverum Biotechnologies announced that on September 3, 2024, the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 12,660 shares of common stock and restricted stock units for 6,330 shares of common stock to 3 new employees under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $6.76 per share, Adverum's closing trading price on September 3, 2024, and will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and, 1/48th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. Each of the RSUs will vest over three years, with 33 1/3% of the underlying shares vesting on each anniversary of September 3, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. The awards are subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

07:32 EDT Rigel Pharmaceuticals: First patient enrolled in Phase 1b/2 REZLIDHIA trial - Rigel Pharmaceuticals announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA in patients with mutated isocitrate dehydrogenase-1 acute myeloid leukemia. REZLIDHIA is a potent, selective, oral, small-molecule inhibitor of mIDH11, designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells, that is approved for the treatment of relapsed or refractory mIDH1 AML.

07:24 EDT Interactive Strength secures distribution for CLMBR in Switzerland, Austria - Interactive Strength has secured exclusive distribution and an initial order for CLMBR in Switzerland and Austria. Trent Ward, Co-Founder and CEO of TRNR, said: "We continue to have success with top-tier distributors, and Domitner in Switzerland and Austria is no exception. We are honored by their support and are looking forward to fulfilling this order as soon as we receive the appropriate European certification, which is expected to be in the third quarter. Following on the significant orders from our German and Gulf region distributors in July, it is clear that there is strong global demand for CLMBR and we are excited about the international opportunity for CLMBR. We expect that we will receive additional orders from other European distributors during 2024 and that we will achieve our guidance of more than ten international customers this year. The international opportunity is expected to be similar in size to the US."

07:23 EDT Extreme Networks: NFL clubs deploying 'Wi-Fi Solutions' for Fan experience - Extreme Networks announced that several NFL Clubs, including the Chargers, Packers, Texans and Vikings, are deploying a variety of innovative solutions from Extreme to dramatically enhance fan experiences, improve operational efficiency and ensure reliable, high-speed Wi-Fi connectivity for seamless game-day activities. Today, 27 NFL teams are leveraging Extreme solutions such as Wi-Fi 6E and ExtremeCloud Business Insights for Venues to create seamless Wi-Fi connectivity across stadiums and practice facilities. The 2024 NFL season marks Extreme's twelfth consecutive season as the league's official provider of Wi-Fi Solutions and Wi-Fi Analytics.

07:20 EDT D-Wave Quantum joins Chicago Quantum Exchange as corporate partner - D-Wave Quantum has joined the Chicago Quantum Exchange CQE as a corporate partner. The company, which serves a wide range of industries, helps customers derive value from today's quantum technologies by solving complex computational problems spanning optimization, research and artificial intelligence. It aims to engage with the CQE community on materials science research, quantum education, and the development of practical optimization use cases, including for the manufacturing and logistics industries. "Quantum computing has the potential to create new paths for solving some of society's most difficult challenges, but to realize this vision, we need to accelerate industry adoption and ensure that the future quantum workforce has access to education programs geared toward real-world applications," said David Awschalom, the Liew Family Professor in Molecular Engineering and Physics at the University of Chicago and the director of the Chicago Quantum Exchange. "We look forward to collaborating with D-Wave to advance these shared goals."

07:19 EDT Draganfly receives purchase order for Commander 3XL, Flex FPV Drones - Draganfly announces that it has received a purchase order from Virtual Reality Rehab acting as the prime contractor for Commander 3XL and Flex FPV Drones to be deployed within the U.S. DOD for various mission types. VRR performs a variety of US government Projects in fields such as: virtual reality training systems, augmented reality operations systems, small Unmanned Aircraft Systems, and human-robotics interfaces.

07:18 EDT BioNTech to present data updates across mRNA, immunomodulatory portfolio - BioNTech SE will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches. Highlights of BioNTech's clinical stage programs to be presented at ESMO Congress 2024: Updates on several Phase 2 and Phase 1/2 clinical trials evaluating BNT327/PM8002 in various indications as monotherapy and in combination with chemotherapy will be presented; Preliminary data from an ongoing clinical Phase 2 trial evaluating BNT113 in combination with PD-1 blockade and data from an investigator-initiated Phase 1/2 clinical trial ; Preliminary data of the randomized Phase 2 clinical trial with BNT316/ONC-392; Follow-up data of activity and immune responses from the ongoing first-in-human Phase 1 clinical trial.

07:15 EDT BioCryst appoints Fong as Chief Medical Officer - BioCryst Pharmaceuticals announced that Donald Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joined BioCryst in April 2024 as vice president of the ophthalmology therapeutic area.

07:15 EDT Capital Bancorp, Integrated Financial announce receipt of approvals for merger - Capital Bancorp and Integrated Financial Holdings announced the receipt of regulatory approval from the Office of the Comptroller of the Currency for the proposed merger of IFH with and into CBNK. CBNK previously announced that it has also received approval from the Federal Reserve Bank of Richmond, acting on delegated authority from the Board of Governors of the Federal Reserve System, for the merger. The merger, which was announced March 28, 2024, was also approved by the shareholders of both CBNK and IFH on August 15, 2024. The parties have now received all required approvals necessary to consummate the merger, which remains subject to other customary closing conditions. Assuming the conditions are satisfied, CBNK and IFH are expected to complete the merger early in the fourth quarter of 2024.

07:13 EDT Talen Energy increases share repurchase program capacity to $1.25B - Talen Energy announced that its board of directors has approved upsizing its previously announced share repurchase program, increasing remaining capacity to $1.25 billion. In October 2023, the board of directors approved a $300 million share repurchase program, which was subsequently upsized to $1 billion through December 31, 2025. To date, Talen has repurchased approximately 14% of its shares outstanding for a total of $931 million. Going forward, the Company is authorized to repurchase up to $1.25 billion of incremental outstanding common stock through the fourth quarter of 2026.

07:10 EDT RedHill Biopharma regains Nasdaq compliance - RedHill Biopharma announced that it received confirmation from the Listings Qualifications Department of The Nasdaq Stock Market that the company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the company was required to maintain a minimum closing bid price for its American Depositary Shares of $1.00 per share or more for at least 10 consecutive business days, which was achieved on September 3, 2024.

07:09 EDT Transcode Therapeutics awarded $2M NIH grant to support TTX-MC138 - TransCode Therapeutics announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research, SBIR, grant from the National Institutes of Health, NIH, to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.

07:08 EDT Eyenovia announces Formosa granted Taiwan Export License - Eyenovia announced that its strategic partner, Taiwan-based Formosa Pharmaceuticals, was granted a Taiwan Export License for clobetasol propionate ophthalmic suspension 0.05% to allow for shipment of commercial product to the U.S. "Clobetasol is the first new ophthalmic steroid to be approved in the U.S. in over 15 years, with benefits that may position it as a leading choice for postsurgical care," said Dr. Francis S. Mah, Director of the Cornea Service at Scripps Clinic in La Jolla, California and member of the Eyenovia Scientific Advisory Board. "Clinical studies have shown that 80% of patients experienced rapid, complete relief from postsurgical pain within four days of the procedure, and 60% achieved total resolution of inflammation within 15 days after surgery. From a safety perspective, fewer than 1% of patients experienced an increase in eye pressure, a side effect of concern to ocular surgeons and commonly associated with steroids."

07:07 EDT First Majestic to acquire Gatos Silver for $13.49 per share - First Majestic Silver Corp. (AG) and Gatos Silver (GATO) have entered into a definitive merger agreement pursuant to which First Majestic will acquire all of the issued and outstanding common shares of Gatos. Gatos is a silver dominant producer with a 70% interest in the Los Gatos Joint Venture, which owns the producing Cerro Los Gatos underground silver mine in Chihuahua, Mexico. Under the terms of the Definitive Agreement, Gatos shareholders will receive 2.550 common shares of First Majestic for each common share of Gatos held. The consideration implies a total offer value of $13.49 per common share of Gatos based on the closing price of First Majestic's common shares on the New York Stock Exchange) on September 4, 2024, and represents a 16% premium based on each company's closing prices and 20-day volume weighted average prices on the NYSE ending September 4, 2024. The proposed Transaction implies a total equity value for Gatos of approximately $970 million. Following completion of the Transaction, existing Gatos shareholders will own approximately 38% of First Majestic shares on a fully-diluted basis. TRANSACTION HIGHLIGHTS: Consolidates three world-class, producing silver mining districts in Mexico under one banner: Cerro Los Gatos, San Dimas and Santa Elena collectively provide the foundation of a diversified, intermediate primary silver producer; Enhances production profile with strong margins: Combined annual production of 30-32 million ounces of silver-equivalent, including 15-16 million ounces of silver at all-in sustaining costs of $18.00-$20.00 per silver-equivalent ounce; Bolsters free cash flow generation: Gatos expected to immediately contribute annual free cash flow of approximately $70 million to the combined entity; Leverages a highly experienced combined team with a strong track record of value creation in Mexico: Over 20 years of experience operating in Mexico, with an emphasis on socially responsible mining, community engagement and value creation; Maintains peer-leading exposure to silver: Over 50% of pro forma revenue derived from silver compared to an average of ~30% for intermediate silver producing peers; Creates a 350,000 hectare highly prospective land package which has yielded a history of exploration success and economic discoveries: Cerro Los Gatos contributes approximately 103,000 hectares of unencumbered land with significant new discovery potential to an existing package of approximately 245,000 hectares across San Dimas, Santa Elena, and other First Majestic properties, which has yielded a history of exploration success and economic discoveries; Results in a larger company with a strengthened balance sheet, leading trading liquidity and improved capital markets profile: Pro forma market capitalization approaching $3 billion, average daily trading liquidity of approximately $49 million, and well-positioned to deliver increased shareholder value; Realizes meaningful synergies: Corporate cost savings, supply chain and procurement efficiencies, cross-pollination of expertise, and acceleration and optimization of internal projects and exploration programs all expected to deliver meaningful value creation for all shareholders. The Transaction will be effected by way of a reverse triangular merger under Delaware law, whereby a wholly-owned Delaware subsidiary of First Majestic will merge with and into Gatos, with Gatos surviving the merger as a direct, wholly-owned subsidiary of First Majestic. Under the terms of the Definitive Agreement, Gatos' shareholders will receive 2.550 common shares of First Majestic for each common share of Gatos held as of the effective date of the Transaction. At closing, First Majestic will issue an aggregate of approximately 177 million common shares to Gatos shareholders, and following completion of the Transaction, existing Gatos shareholders will own approximately 38% of the issued and outstanding common shares of First Majestic on a fully-diluted basis. The Transaction is expected to close in early 2025, subject to the satisfaction of customary closing conditions, including approvals of the shareholders of First Majestic and Gatos, clearance under Mexican anti-trust laws, and approval of the listing of the First Majestic common shares to be issued under the Transaction on both the Toronto Stock Exchange and the NYSE. The Definitive Agreement and the Transaction have been unanimously approved by the board of directors of each of First Majestic and Gatos, and in the case of Gatos, on the unanimous recommendation of a special committee of independent directors of Gatos. All directors and certain executive officers of Gatos, as well as the Electrum Group, which owns approximately 32% of the issued and outstanding common shares of Gatos, have entered into voting support agreements with First Majestic pursuant to which they have agreed, subject to the terms of such agreements, to vote their Gatos shares in favour of the Transaction.

07:05 EDT BRC Inc. announces distribution pact with Keurig Dr Pepper for energy beverages - Black Rifle Coffee (BRCC) unveiled a long-term sales and distribution agreement with Keurig Dr Pepper (KDP) for BRCC's new line of ready-to-drink Black Rifle Energy beverages. The Black Rifle Energy beverage line is expected to launch in Q4 and be available nationwide in early 2025. Under the terms of the agreement, KDP will sell and distribute Black Rifle Energy within the majority of its company-owned direct store territories nationwide.

07:04 EDT Perspective Therapeutics granted Fast Track Designation for VMT01 - Perspective Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or "MC1R," is a protein that can be overexpressed in metastatic melanoma.

07:03 EDT Gilat Satellite secures over $12M orders for SkyEdge Platforms - Gilat Satellite Networks announced that the Company was awarded over $12M of orders from a leading satellite operator to expand their global SATCOM network utilizing Gilat's SkyEdge Family of VSAT Platforms. The deal is expected to be delivered within the upcoming 12 months. This strategic expansion provides significant future revenue prospects. The operator is utilizing Gilat's flexible architecture to ensure robust and seamless communications across diverse orbital assets.

06:58 EDT Timken appoints Tarak Mehta as CEO, member of board - Timken appointed Tarak Mehta the company's president and CEO. Mehta was also elected to Timken's board of directors. Following a search process, the Timken board announced in March that Mehta, who previously served as a member of ABB's group executive committee and president of its Motion business, would succeed Richard Kyle as president and CEO. Mehta succeeds Kyle, who has moved into an advisory role to assist with the leadership transition after 10 years as CEO. Following the transition, Kyle plans to retire as a Timken employee in February 2025, but will continue to serve on the company's board of directors.

06:55 EDT Lion Electric announces all-electric school buses eligible for Dominion program - Lion Electric (LEV) announced that its all-electric school buses are now eligible for Dominion Energy's Electric School Bus Infrastructure program in Virginia. Dominion (D), the main electricity provider in Virginia, is supporting public school districts within its Virginia service territory by providing fast-charging solutions to districts that receive Environmental Protection Agency, or EPA, Clean School Bus funding. As part of this program, Dominion Energy facilitates the coordination of utilities, network upgrades, construction, and installation of charging infrastructure for beneficiary school districts. Additionally, this initiative enables electric school buses to serve as a grid resource. With vehicle-to-grid technology, electric school buses can be utilized as additional energy storage and discharge energy on to the grid during periods of high demand when the buses are not needed for transport.

06:52 EDT The Buckle reports August 2024 comparable sales up 1.7% year over year - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended August 31, 2024 increased 1.7% from comparable store net sales for the 4-week period ended September 2, 2023. Net sales for the 4-week fiscal month ended August 31, 2024 decreased 6.6% to $105.1M from net sales of $112.5M for the prior year 4-week fiscal month ended August 26, 2023. Comparable store net sales year-to-date for the 30-week period ended August 31, 2024 decreased 6.3% from comparable store net sales for the 30-week period ended September 2, 2023. Net sales for the 30-week fiscal period ended August 31, 2024 decreased 5.5% to $650.0M vs. net sales of $687.8M for the prior year 30-week fiscal period ended August 26, 2023.

06:37 EDT Utz Brands still sees 2024 adjusted EPS growth 28%-32% from 87c in 2023 - Consensus for 2024 EPS is 74c. Lowers 2024 organic revenue growth view to 2%-2.5% from approximately 3%. 2023 revenue was $1.44B and consensus for 2024 revenue is $1.43B. The revised outlook is primarily due to the expectation for a more competitive promotional environment in the second half of 2024. "We experienced a strong start in the first half of the year, thanks to our continued focus on our growth strategies and value creation initiatives," said CEO Howard Friedman. "Further, we are executing well on our distribution growth opportunities, which we expect will continue into 2025 and beyond. However, our consumption trends in Q3 to date moderated more than we expected due to a more competitive promotional environment primarily in response to consumer value-seeking behavior. We will continue to make appropriate adjustments to our promotional activities to meet consumer value expectations but will remain disciplined and focused on building sustainable long-term demand. As a result, today we are revising our 2024 Organic Net Sales growth outlook. Our accelerated productivity cost savings give us the flexibility to expand our margins and increase investments in our brands to support our geographic expansion. We remain confident that we are well-positioned to deliver the 2026 targets that we introduced at our Investor Day in December 2023, and that we will successfully navigate this dynamic environment." For the full year fiscal 2024, Utz is reaffirming its outlook for Adjusted EBITDA and Adjusted Earnings per Share growth and Net Leverage Ratio, and revising its Organic Net Sales growth outlook(1): Adjusted EBITDA is expected to grow 5% - 8%, which is consistent with the Company's prior expectation. Adjusted Earnings per Share are expected to grow 28% - 32%, which is consistent with the Company's prior expectation. Net Leverage Ratio is expected to be approximately 3.6x at year-end fiscal 2024, which is consistent with the Company's prior expectation. Capital expenditures in the range of $80 - $90 million.

06:35 EDT Primo Water, BlueTriton Brands report expiration of waiting period under HSR Act - Primo Water and BlueTriton Brands announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced all-stock combination of Primo Water and BlueTriton.

06:33 EDT Babcock & Wilcox awarded contract in Canada - Babcock & Wilcox announced that it has been awarded a contract to conduct front-end engineering and design for Varme Energy's planned waste-to-energy with carbon capture and sequestration project in Alberta, Canada. As part of the contract, B&W will conduct engineering and design for the plant's waste-fired boiler, emissions control technologies and post-combustion carbon capture system.

06:18 EDT Opthea announces executive leadership changes and senior hires - Opthea announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market Access. Daniel Geffken, Co-Founder and Managing Director, Danforth Advisors, will assume the role of interim CFO reporting to CEO Frederic Guerard, effective September 9. Geffken has served as CFO, strategic consultant and board member to dozens of life science companies. Daniel Geffken succeeds Peter Lang who decided to leave the company for personal reasons effective September 9. Mike Campbell has been appointed Chief Commercial Officer. During his tenure at Genentech, he served in commercial leadership roles through the lifecycle of Lucentis and also contributed to the pre-launch commercial planning of Beovu in wet AMD at Novartis. Campbell most recently served as SVP and Head of Commercial at Viatris Eye Care. Mike Campbell succeeds Judith Robertson who will leave the company on September 9 to pursue other opportunities. Dayong Li has been appointed SVP, Biometrics effective September 9. Li most recently served as SVP, Biometrics, at Marinus Pharmaceuticals. Over his career, Li held global Biometrics roles at Forest Laboratories, Astra Zeneca, and other pharmaceutical and biotech companies. Jen Watts has been appointed VP Global Clinical Operations. During recent years, she has held the position of VP, Clinical Operations at several clinical-stage biopharmaceutical companies. Jennifer Watts succeeds Bruno Gagnon, who decided to leave the company on September 9. Anthony Bonifazio has been appointed VP, Market Access, effective September 9. Bonifazio joins Opthea from Astellas where he served as VP, Access, Reimbursement and Market Development. During his tenure at Novartis, Bonifazio built a 180-person organization for the launch of the first physician-administered, buy and bill product in cardiology. Bonifazio started his career in Genentech.

06:10 EDT Beam Global closes acquisition of Europe-based Telcom - Beam Global announced the closing of the acquisition of Telcom, a European based company located in Belgrade, which since 1990 engineers and manufacturers specialized power electronics including invertors, charge controllers, power supplies and LED lighting. Beam Global expects that the acquisition of Telcom will enable the company to enhance its products, improve quality, reduce warranty and service requirements, and reduce costs through the replacement of third-party power electronic components with Beam Global engineered and manufactured solutions. Telcom, now Beam Europe's power electronics team, will be tasked with creating bespoke solutions to replace third-party products enabling Beam Global to retain margin and create products with lower failure rates which are better suited for the unique attributes of Beam's patented product portfolio.

06:07 EDT Verizon sees Frontier Communications deal accretive to revenue, EBITDA - The transaction is expected to be accretive to Verizon's revenue and adjusted EBITDA growth rates upon closing. Verizon expects to realize at least $500M in run-rate cost synergies by year three from benefits of increased scale and distribution and network integration. Following the closing of the transaction, Verizon will continue to have a strong balance sheet and liquidity profile. The company will maintain its capital allocation priorities, characterized by prudent investment in the business, a commitment to maintaining an industry-leading dividend and continued debt reduction.

06:04 EDT Honeywell CFO Greg Lewis to switch roles, Mike Stepniak to succeed - Honeywell announced that Mike Stepniak, who currently serves as VP and CFO for Honeywell Aerospace Technologies, will succeed Greg Lewis as senior VP and CFO following the company's announcement of its fourth quarter and full-year financial results for fiscal year 2024. Until the transition is complete, Stepniak will serve as VP, corporate finance. Upon completion of the transition, Lewis, who has been Honeywell's CFO since 2018 and served the company for nearly two decades, will become senior VP of Honeywell Accelerator and serve as a senior advisor to chairman and CEO Vimal Kapur.

06:02 EDT McKesson selling Rexall and Well.ca businesses to Birch Hill Equity Partners - McKesson has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. McKesson Canada intends to remain a wholesale distribution supplier to each business. McKesson Canada will continue to own and operate Rexall and Well.ca until transaction close, which is subject to customary closing conditions, including necessary regulatory clearances.

05:38 EDT Microsoft's acquihire of Inflection's team cleared by U.K.'s CMA - The U.K.'s Competition and Markets Authority has cleared Microsoft's hiring of certain former employees of Inflection and its entry into associated arrangement with Inflection. The CMA found that the transaction "is a relevant merger situation falling within the merger control jurisdiction of the CMA but that the transaction does not give rise to a realistic prospect of a substantial lessening of competition as a result of horizontal unilateral effects," the CMA said in a statement. Reference Link

05:28 EDT Highway Holdings receives initial order of 100,000 units - Highway Holdings announced the company received an initial order of 100,000 units for a new model of brushless electric motor from one of its largest strategic customers. The new motor was designed and manufactured by the company specifically for such customer, with the company serving as the original design manufacturer, or ODM, rather than as an original equipment manufacturer.

05:21 EDT Teva provides update on Olanzapine LAI trial - Teva Pharmaceuticals announced during the 22nd Annual Global Healthcare Conference held yesterday that confidence interval 99% of the targeted injections for submission have been performed. Teva also confirmed that the full submission safety results are expected to be available in the second half. Olanzapine LAI is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic Olanzapine. Teva is fully responsible for leading the development and commercialization of Olanzapine LAI. Medincell may receive up to $117M in development and commercial milestones for mdc-TJK, in addition to royalties on all net sales of both products.

05:13 EDT Accenture, Unilever expand strategic partnership - Accenture (ACN) has expanded its strategic partnership with Unilever (UL) to simplify its digital core and apply generative AI to drive efficiencies and improved business agility. Announcing this multi-year program, Unilever will work with Accenture to establish gen AI powered productivity. This collaboration builds on the previously announced effort to explore applications to scale gen AI across Unilever's business operations. Since then, Unilever has focused efforts on identifying and testing new AI concepts, designs and projects from its "Horizon3 Labs."